George Sledge, M.D. is the Ballvé-Lantero Professor of Oncology at Indiana University at Indianapolis, where he co-directs Indiana University Simon Cancer Center's Breast Cancer Program. He is a leader in researching new treatments for breast cancer, and is exploring the use of angiogenesis blockers, or disruption of the blood supply, in the treatment of breast cancer. He currently serves as chair of the Eastern Cooperative Oncology Group's Breast Cancer Committee, and is a member of the American Society of Clinical Oncology's Board of Directors. Dr. Sledge also serves on the advisory board of the Triple-Negative Breast Cancer Foundation.
Can we help guide you?
Create a profile for better recommendations
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
Triple-Negative Breast Cancer
Triple-negative breast cancer is cancer that tests negative for estrogen receptors, progesterone...